Collegium Pharmaceutical (354) AI Stock Analysis
Collegium Pharmaceutical
(Frankfurt:354)
No summary available
Collegium Pharmaceutical (354) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 774.82M
- Dividend Yield
- ―
- Average Volume (3M)
- 70
- Price to Earnings (P/E)
- 15.6
- Beta (1Y)
- 0.75
- Revenue Growth
- 6.56%
- EPS Growth
- 25.86%
- Country
- Germany
- Employees
- 423
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Collegium Pharmaceutical Business Overview & Revenue Model
Company Description
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain condi...
Collegium Pharmaceutical Earnings Call Summary
The call highlighted strong, accelerating growth in the ADHD franchise—Jornay PM momentum, the strategic Azstarys acquisition with early revenue and raised guidance, Belbuca growth and incremental formulary wins, and an 8% increase in adjusted EBITDA. Offsetting these positives were meaningful declines in the NUCYNTA franchise driven by authorized generic pricing, a decline in Xtampza ER, a GAAP net loss driven by acquisition-related costs, substantial cash deployed to acquire Azstarys and a modest leverage increase, and potential LOE risk for Belbuca. Overall, management presented a constructive outlook focused on ADHD-led growth and disciplined capital deployment while acknowledging near-term pain portfolio pressures and one-time acquisition impacts.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Collegium reaffirmed full‑year guidance for Jornay PM of $190–200 million and raised its Azstarys outlook to $65–75 million, driving updated total product revenue guidance of $825–855 million (about +8% year‑over‑year at the midpoint); adjusted EBITDA was guided to $445–470 million (essentially flat vs. 2025) and Jornay PM gross‑to‑net is expected to remain in the mid‑60% range. Management said the guidance update primarily reflects lower‑than‑expected NUCYNTA revenue due to authorized generic pricing, noted Azstarys generated $12.9 million of initial sales in Q2, and reported Q2 operating cash flow of $71.3 million, ending cash and marketable securities of $129.5 million after using approximately $356 million to fund the Azstarys acquisition, with net debt to adjusted EBITDA of ~2.1x.
Collegium Pharmaceutical Risk Analysis
Collegium Pharmaceutical disclosed 43 risk factors in its most recent earnings report. Collegium Pharmaceutical reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
1 New RiskCollegium Pharmaceutical Peers Comparison
Overall Rating
ANIP75Outperform
PCRX62Neutral
INDV60Neutral
AMRX59Neutral
AQST49Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ANIP | 75Outperform | $1.65B | 14.91 | 19.19% | ― | 30.90% | ― |
| PCRX | 62Neutral | $1.45B | 103.35 | 2.13% | ― | 5.71% | ― |
| INDV | 60Neutral | $4.17B | 9.66 | -352.94% | ― | 16.44% | 265.06% |
| AMRX | 59Neutral | $7.49B | 43.24 | -326.75% | ― | 9.28% | 4917.17% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AQST | 49Neutral | $488.24M | -5.98 | 243.68% | ― | 22.56% | 5.86% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:354 | Collegium Pharmaceutical Inc. | 21.00 | -9.80 | -31.82% | |
| PCRX | Pacira | 36.39 | 14.20 | 63.99% | |
| ANIP | Ani Pharmaceuticals | 72.00 | -22.06 | -23.45% | |
| INDV | Indivior PLC | 35.37 | 4.17 | 13.37% | |
| AMRX | Amneal Pharma | 21.51 | 10.32 | 92.14% | |
| AQST | Aquestive Therapeutics, Inc. | 3.89 | -2.60 | -40.06% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.